MPNE at ASCO 2015- Bettina will blog about all things Melanoma!
Tuesday, 26 May 2015
Noteworthy ASCO findings
Let's collect anything interesting you picked up when going through the ASCO abstracts or online communication or publications or anything else related to ASCO 2015 under here- together we see more!
Abstract of high interest although not a big surprise anymore: ipilimumab+ nivolumab almost doubled progression free survival in comparison with ipilimumab alone: 8,9 vs 4,7 months Overall response rate was 60% for combi vs 11% for IPI alone. No complet response was observed in the IPI arm. Also better responses rates on combi - for the patients with poor prognostic factors. http://abstracts.asco.org/156/AbstView_156_144615.html
http://abstracts.asco.org/156/AbstView_156_148865.html Here, data from a very small cohort- encouraging use of pembrolizumab for patients with metastatic uveal melanoma. One patient had complete response, one - partial response and one-stable disease. PFS was 12.2 weeks and two patients are still receiving therapy.
http://abstracts.asco.org/156/AbstView_156_152690.html - ...and here is a study (8 cases) on the etiology of uveal melanoma showing that distinctive agents might cause the disease.
Dabrafenib +Trametinib vs Dabrafenib (CombiD) - data from live asco presentation today via Bettina - 29% reduction in risk of death combo over monoteraphy 25.1 vs 18.7 months PFS in favour of the combo 2-year OS- > 50% on combination no data in the abstract http://abstracts.asco.org/156/AbstView_156_149861.html
Clinical characteristics correlated with higher response to pembrolizumab http://abstracts.asco.org/156/AbstView_156_145183.html -the data are from a phase I trial - 110 patients and ORR = 40% Higher ORR reported when: - LDH ≤ normal (ORR 52.2%), - no previous ipilimumab (ORR 48.3%), - presence of lung metastasis (ORR 52.8%). Patients with liver metastasis had worse response (ORR 18.4%), as did those with liver and lung metastases (ORR 31.3%)
ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases - the median follow-up of 35 months shows no significant differences in 3-year and 5-year recurrence-free survival and melanoma-specific survival. http://www.ascopost.com/ViewNews.aspx?nid=28616&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292
Linked to this article Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930354/, a presentation of Dummer ''he recommends cycling through targeted therapies: immunotherapies and then going back on targeted -a more holistic approach.
Related to an ASCO presentation - Efficacy of MEK Inhibition in Uveal Melanoma http://jama.jamanetwork.com/article.aspx?articleid=1881312 on the drug selumetinib vs chemotheraphy in uveal melanoma: - median survival 9.1 months on chemotherapy vs 11.8 months selumetinib - PFS - 7 weeks chemo vs 15.9 weeks selumetinib - OS - no improvement - selumetinib is giving fast responses, good PFS but not improvement in OS. ( it can be good as a ''bridge'')
TAPUR- a Non Randomized Clinical Trial collecting real-world data in various cancers http://www.ascopost.com/ViewNews.aspx?nid=28617&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292
Adjuvant anti-PD-1 clinical trials- http://abstracts.asco.org/156/AbstView_156_151015.html Immune markers suporting the use of anti-PD1 as adjuvant theraphy
Circulating melanoma cells (CMC) is linked with high risk recurrence in stage III melanoma patients - http://meetinglibrary.asco.org/content/152274-156
BRAFi ENCO (LGX818) and MEKi BINI (MEK162) -- each shown promising single-agent activity in BRAFV600–mutant melanoma 78 and 72% respectively confirmed RR in phase Ib/II. - http://abstracts.asco.org/156/AbstView_156_146432.html Related -- a Ph III trial Columbus with these agents (US and Europe) https://clinicaltrials.gov/ct2/show/study/NCT01543698#contacts
Abstract of high interest although not a big surprise anymore: ipilimumab+ nivolumab almost doubled progression free survival in comparison with ipilimumab alone: 8,9 vs 4,7 months Overall response rate was 60% for combi vs 11% for IPI alone. No complet response was observed in the IPI arm. Also better responses rates on combi - for the patients with poor prognostic factors. http://abstracts.asco.org/156/AbstView_156_144615.html
ReplyDeletehttp://abstracts.asco.org/156/AbstView_156_148865.html Here, data from a very small cohort- encouraging use of pembrolizumab for patients with metastatic uveal melanoma. One patient had complete response, one - partial response and one-stable disease. PFS was 12.2 weeks and two patients are still receiving therapy.
ReplyDeletehttp://abstracts.asco.org/156/AbstView_156_152690.html - ...and here is a study (8 cases) on the etiology of uveal melanoma showing that distinctive agents might cause the disease.
ReplyDeleteDabrafenib +Trametinib vs Dabrafenib (CombiD) - data from live asco presentation today via Bettina -
ReplyDelete29% reduction in risk of death combo over monoteraphy
25.1 vs 18.7 months PFS in favour of the combo
2-year OS- > 50% on combination
no data in the abstract http://abstracts.asco.org/156/AbstView_156_149861.html
Clinical characteristics correlated with higher response to pembrolizumab
ReplyDeletehttp://abstracts.asco.org/156/AbstView_156_145183.html
-the data are from a phase I trial - 110 patients and ORR = 40%
Higher ORR reported when:
- LDH ≤ normal (ORR 52.2%),
- no previous ipilimumab (ORR 48.3%),
- presence of lung metastasis (ORR 52.8%).
Patients with liver metastasis had worse response (ORR 18.4%), as did those with liver and lung metastases (ORR 31.3%)
ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases - the median follow-up of 35 months shows no significant differences in 3-year and 5-year recurrence-free survival and melanoma-specific survival. http://www.ascopost.com/ViewNews.aspx?nid=28616&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292
ReplyDeleteThis comment has been removed by the author.
ReplyDeleteLinked to this article Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930354/, a presentation of Dummer ''he recommends cycling through targeted therapies: immunotherapies and then going back on targeted -a more holistic approach.
ReplyDeleteRelated to an ASCO presentation - Efficacy of MEK Inhibition in Uveal Melanoma http://jama.jamanetwork.com/article.aspx?articleid=1881312
ReplyDeleteon the drug selumetinib vs chemotheraphy in uveal melanoma:
- median survival 9.1 months on chemotherapy vs 11.8 months selumetinib
- PFS - 7 weeks chemo vs 15.9 weeks selumetinib
- OS - no improvement
- selumetinib is giving fast responses, good PFS but not improvement in OS.
( it can be good as a ''bridge'')
TAPUR- a Non Randomized Clinical Trial collecting real-world data in various cancers http://www.ascopost.com/ViewNews.aspx?nid=28617&utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=4210292
ReplyDeleteThis comment has been removed by the author.
ReplyDeleteNeoadjuvant BRAF (dabrafenib) and MEK (trametinib)
ReplyDeletehttp://abstracts.asco.org/156/AbstView_156_152525.html
Adjuvant anti-PD-1 clinical trials- http://abstracts.asco.org/156/AbstView_156_151015.html
ReplyDeleteImmune markers suporting the use of anti-PD1 as adjuvant theraphy
Circulating melanoma cells (CMC) is linked with high risk recurrence in stage III melanoma patients - http://meetinglibrary.asco.org/content/152274-156
ReplyDeleteBRAFi ENCO (LGX818) and MEKi BINI (MEK162) -- each shown promising single-agent activity in BRAFV600–mutant melanoma 78 and 72% respectively confirmed RR in phase Ib/II. - http://abstracts.asco.org/156/AbstView_156_146432.html
ReplyDeleteRelated -- a Ph III trial Columbus with these agents (US and Europe) https://clinicaltrials.gov/ct2/show/study/NCT01543698#contacts
This comment has been removed by the author.
ReplyDeleteIPILIMUMAB and T-VEC (oncolytic virus) http://abstracts.asco.org/156/AbstView_156_151884.html
ReplyDelete- Overall Response Rate -56%
- Complete Responses -33%
- Durable Response Rate -44%.
- Median progression-free survival (PFS) -10.6 months
- Median overall survival (OS) - not reached;
- 12-month and 18-month survival- 72.2% and 67%.
- 50% of uninjected lesions responded
Phase 2 (ipi vs T-VEC+ipi) is ongoing